Marsh & McLennan insider files Form 144 to sell 21,079 shares
Rhea-AI Filing Summary
Marsh & McLennan Companies, Inc. (MMC) filed a Form 144 reporting a proposed sale of 21,079 common shares through Fidelity Brokerage Services (Smithfield, RI) with an aggregate market value of $4,334,896.35. The filing lists the approximate date of sale as 09/02/2025 and reports 491,624,043 shares outstanding, indicating the sale will be executed on the NYSE. The securities are reported as acquired in connection with options granted 05/01/2016, with the acquisition date shown as 09/02/2025 and payment noted as cash. The filer also disclosed a prior sale on 06/02/2025 by John Q. Doyle of 21,080 shares for gross proceeds of $4,891,614.00. The notice includes the standard representation that the selling person does not possess undisclosed material adverse information.
Positive
- Detailed disclosure of broker, share count, aggregate market value, acquisition source, and intended sale date
- Includes prior sale data (21,080 shares on 06/02/2025 for $4,891,614), improving transparency on insider dispositions
Negative
- None.
Insights
TL;DR Routine insider filing disclosing planned sale of vested option shares; no new financial performance data.
The Form 144 details a proposed sale of 21,079 common shares via a broker with an aggregate market value of $4.33 million, to be executed on 09/02/2025 on the NYSE. The securities are reported as originating from options granted in 2016, which suggests exercise/vesting events rather than market-driven dispositions. A recent, nearly identical sale of 21,080 shares on 06/02/2025 produced roughly $4.89 million in proceeds. For investors, this filing documents insider liquidity activity but does not provide company operational or earnings information.
TL;DR Filing appears procedurally complete for Rule 144 disclosure and includes required seller certification.
The notice identifies the broker, share count, aggregate value, outstanding shares, acquisition source (options granted 05/01/2016), and sale date, meeting core Form 144 disclosure elements. The filing includes the standard signature/representation regarding lack of undisclosed material adverse information and references Rule 10b5-1 considerations. There is no indication of omitted mandatory fields within the provided content, though several issuer-identifying fields in the header are blank in this extract.